The role of peroxynitrite in hypoxia-reoxygenation-induced coronary vasospasm was investigated in isolated bovine coronary arteries. Hypoxia-reoxygenation selectively blunted prostacyclin (PGI 2 )-dependent vasorelaxation and elicited a sustained vasoconstriction that was blocked by a cyclooxygenase inhibitor, indomethacin, and SQ29548, a thromboxane (Tx)A 2 / prostaglandin H 2 receptor antagonist, but not by CGS13080, a TxA 2 synthase blocker. The inactivation of PGI 2 synthase, as evidenced by suppressed 6-keto-PGF 1 ␣ release and a decreased conversion of 14 C-prostaglandin H 2 into 6-keto-PGF 1 ␣ , was paralleled by an increased nitration in both vascular endothelium and smooth muscle of hypoxia-reoxygenation-exposed vessels. The administration of the nitric oxide (NO) synthase inhibitors as well as polyethylene-glycolated superoxide dismutase abolished the vasospasm by preventing the inactivation and nitration of PGI 2 synthase, suggesting that peroxynitrite was implicated. Moreover, concomitant administration to the organ baths of the two precursors of peroxynitrite, superoxide, and NO mimicked the effects of hypoxia-reoxygenation, although none of them were effective when given separately. We conclude that hypoxia-reoxygenation elicits the formation of superoxide, which causes loss of the vasodilatory action of NO and at the same time yields peroxynitrite. Subsequently, peroxynitrite nitrates and inactivates PGI 2 synthase, leaving unmetabolized prostaglandin H 2 , which causes vasospasm, platelet aggregation, and thrombus formation via the TxA 2 /prostaglandin H 2 receptor.
U nder physiological conditions, the endothelium provides vasodilatory and antiaggregatory properties to the cardiovascular system and also prevents growth of the underlying vascular smooth muscle cells by releasing nitric oxide (NO), endothelium-derived hyperpolarizing factor, and prostacyclin (PGI 2 ) (1-3). Each of these mediators acts by a different mechanism, NO by the stimulation of guanylyl cyclase (2) and PGI 2 by activating adenylyl cyclase, so that these mediators can act synergistically and also serve as backup systems for each other (1) (2) (3) . It was interesting to study this interdependence after a selective inhibition of PGI 2 synthase by peroxynitrite had been described (4) . As peroxynitrite is generated in vivo by a rapid combination of NO and superoxide radicals (O 2 . Ϫ ) (5, 6) , it seemed that O 2
. Ϫ not only can neutralize NO but subsequently, through its product peroxynitrite, could suppress PGI 2 formation. The underlying mechanism for PGI 2 synthase blockade has been suggested as the nitration of a tyrosine residue at the active site through a reaction catalyzed by the ferric iron of this heme-thiolate (P450) protein (7) . In spite of the cellular antioxidant potential, peroxynitrite causes PGI 2 synthase nitration in whole cells (8) as well as in intact coronary arteries (9) . Endothelial dysfunction (impaired vasorelaxation and/or increased vasoconstriction) is an important early-recurring phenomenon in virtually all forms of ischemia/reperfusion diseases, including a variety of shock states (10) . This dysfunction appears to be triggered simultaneously with the endothelial generation of O 2 . Ϫ . Therefore, the formation of peroxynitrite during hypoxia-reoxygenation is likely because of a simultaneous generation of NO and O 2 . Ϫ (11). In this study, we investigated a role of peroxynitrite in hypoxia-reoxygenation-induced coronary vasospasm by monitoring the pattern of angiotensin II-triggered vasoconstriction/vasorelaxation, PGI 2 release, and the nitration of PGI 2 synthase. Our results suggest that hypoxia-reoxygenation elicits peroxynitrite formation, leading to a subsequent nitration and inhibition of PGI 2 synthase. Most importantly, the unmetabolized PGH 2 triggers vasospasm by acting upon the thromboxane (Tx)A 2 /PGH 2 receptor before being converted to PGE 2 .
136
Hypoxia-Reoxygenation Causes Nitration of Prostacyclin Synthase
Materials and Methods
Materials. All chemicals, if not indicated otherwise, were obtained from the same sources as previously described (9) . N -monomethyl-l -arginine (L-NMMA), N -nitro-l -arginine methyl ester (L-NAME), and diethylamine NONoate (DEA-NO) were obtained from Cayman SPI. Polyethylene-glycolated superoxide dismutase (PEG-SOD) was obtained from Sigma Chemical Co. 14 C-PGH 2 was prepared from 14 C-arachidonic acid as previously described (4, 7) . Rabbit anti-PGI 2 synthase antisera were produced in this laboratory as previously described (12) .
Experimental Protocol. As previously described (9), bovine coronary arteries (BCA) of the left ventricle were isolated and resuspended in a tissue bath with 15 ml of Krebs buffer, gassed with 95% O 2 /5% CO 2 (37 Њ C; pH 7.4), and attached to a force-displacement TFT6V5 transducer coupled to a polygraph for the measurement of isometric tension. Passive tension was adjusted to ‫ف‬ 1 g over a 30-min equilibrating period, and then coronary arteries were preconstricted by addition of the Tx mimetic U46619 (0.001-0.01 mol/liter). The vasorelaxation after acetylcholine (0.01-1 mol/liter) was used to demonstrate the presence of endothelium-dependent relaxation. Throughout the experiment, care was taken to avoid any injury to the endothelium.
Experiments were started by obtaining from each spiral a reference response of vasoconstriction-relaxation with angiotensin II (50 nM) for 30 min. After removal of the agonist from the chambers and return of tone to basal levels, the oxygen tension was then reduced abruptly from 95% O 2 /5% CO 2 to 95% N 2 /5% CO 2 (hypoxia, PO 2 ϭ 10 Ϯ 3 mmHg) and was maintained for 10-, 30-, or 40-min hypoxia. After this phase of hypoxia, 95% O 2 /5% CO 2 was resumed (reoxygenation), and the tension was allowed to stabilize for 40 min before addition of agonists. If required, pharmacological agents were added in the organ chamber 40 min before hypoxia and kept during hypoxia-reoxygenation and the second stimulation with the agonists. Tissues were kept for immunohistochemistry or immunoprecipitation and Western blots. The media from the first and second stimulations with angiotensin II were collected and stored at Ϫ 20 Њ C for prostanoid analysis, as previously described (9), using ELISA kits according to the manufacturer's instructions.
Activity Assay of PGI 2 Synthase. BCA spirals with or without hypoxia-reoxygenation were incubated with 100 M 14 C-PGH 2 for 3 min as previously described (4, 7, 9) . The reaction was stopped by acidification with 1 N HCl to pH 3.5. The incubation media were extracted with ethyl acetate (3 vol). After centrifugation, the organic phases were evaporated to dryness under nitrogen. Samples were then resuspended in 60 l of ethyl acetate and subsequently separated by TLC (ethyl acetate/water/iso-octane/ acetic acid, 90:100:50:20). Prostanoids were quantified with a PhosphorImager system (ImageQuant; Molecular Dynamics).
Immunohistochemistry, Immunoprecipitation, and Western Blots. Immunohistochemistry, immunoprecipitation, and Western blots of 3-nitrotyrosine-containing protein in hypoxia-reoxygenationtreated BCA were performed as previously described (9) .
Results and Discussion
In BCA, angiotensin II elicited a biphasic response consisting of a primary vasoconstriction that was selectively blocked by losartan, a selective angiotensin 1 receptor blocker, and a secondary vasorelaxation that was mainly PGI 2 dependent (9).
Abrupt decrease of oxygen tension from 95% O 2 /5% CO 2 to 95% N 2 /5% CO 2 caused a slight decrease in tension after a transient rise. Reoxygenation (from 95% N 2 / 5% CO 2 to 95% O 2 /5% CO 2 ) did not alter the tension of unstimulated arteries. Although hypoxia-reoxygenation did not affect the initial constriction of angiotensin II, it selectively blunted the angiotensin II-triggered relaxation phase after 30 min of hypoxia. Along with this suppression of the relaxation phase, a second constriction phase developed in parallel, with a decrease of 6-keto-PGF 1 ␣ (Fig. 1 A) that closely resembled the pattern seen previously after peroxynitrite pretreatment (9) .
Both the COX (cyclo-oxygenase) inhibitor indomethacin and the TxA 2 /PGH 2 receptor blocker SQ29548 restored hypoxia-reoxygenation-impaired relaxation without affecting 6-keto-PGF 1 ␣ release (Fig. 1 A) . This suggests that a COX-derived product, TxA 2 or PGH 2 , caused vasoconstriction via the TxA 2 /PGH 2 receptor (Fig. 1 A) . A role of TxA 2 was excluded, as CGS13080, a TxA 2 synthase inhibitor, did not affect hypoxia-reoxygenation-triggered vaso- SQ 29548, CGS13080, SOD, L-NMMA, and L-NAME on angiotensin IItriggered relaxation (white bars) and the release of 6-keto-PGF 1␣ (black bars) and PGE 2 (hatched bars) in hypoxia-reoxygenated BCA. After having obtained a reference response to angiotensin II, the coronary strip was exposed to hypoxia for 40 min after 40-min reoxygenation in presence of indomethacin (10 M), CGS13080 (10 M), SQ-29548 (10 M), PEG-SOD (500 U/ml), L-NMMA (10 Ϫ4 M), or L-NAME (10 Ϫ4 M). PGE 2 and 6-keto-PGF 1␣ in the media were analyzed by ELISA. Data represent means Ϯ SEM from 10 experiments. (B) Effects of superoxide, NO, and concurrent administration of superoxide and NO on angiotensin II-induced vasorelaxation and prostaglandin release in BCA. After having obtained a reference response to angiotensin II, the coronary strip was exposed to superoxide generated from 10 mU/ml xanthine oxidase/100 M hypoxanthine or to NO generated from 20 M DEA-NO or superoxide plus NO. PGE 2 (hatched bars) and 6-keto-PGF 1␣ (black bars) in the media were analyzed by ELISA. Data represent means Ϯ SEM from 12 experiments. White bars, relaxation. spasm ( Fig. 1 A) , and the levels of TxB 2 remained low and unaffected after hypoxia-reoxygenation treatment (97 Ϯ 11 vs. 99 Ϯ 15 pg/30 min). The level of 8-iso-PGF 2 ␣ , which also could act on the TxA 2 /PGH 2 receptor (14), was low and remained unchanged after hypoxia-reoxygenation (43 Ϯ 12 vs. 47 Ϯ 17 pg/30 min).
PGH 2 is known to cause vasoconstriction via the TxA 2 / PGH 2 receptor (13). In arterial vessels, PGI 2 is metabolized primarily by PGI 2 synthase to yield PGI 2 . Therefore, we postulated that an inhibition on PGI 2 synthase could be the primary cause for the accumulation of PGH 2 , which then caused vasoconstriction by stimulating the TxA 2 /PGH 2 receptor. Parallel measurements of prostaglandins in the incubation medium further supported this hypothesis. Hypoxia-reoxygenation lowered 6-keto-PGF 1␣ formation but raised the level of PGE 2 , an enzymatic or nonenzymatic metabolite of PGH 2 (Fig. 1 A) . As COX activity was slightly decreased after hypoxia-reoxygenation, an excess formation of PGH 2 after hypoxia-reoxygenation could be excluded.
Conclusive evidence for an inactivation of PGI 2 synthase came from the experiments with 14 C-PGH 2 as a substrate for PGI 2 synthase. A significant inhibition on the conversion of 14 C-PGH 2 into 6-keto-PGF 1␣ (Ϫ89 Ϯ 8%) with a concomitant increase of PGE 2 (135 Ϯ 21%) was observed, confirming the selective inhibition of PGI 2 synthase and the reorientation of PGH 2 metabolism toward PGE 2 after hypoxia-reoxygenation.
The sustained vasoconstriction after hypoxia-reoxygenation could also have been the consequence of a decreased sensitivity of vascular smooth muscle to NO. However, NO generated from DEA-NO in arteries with or without hypoxia-reoxygenation resulted in a similar potency to induce vasorelaxation. Similarly, an increased sensitivity of the TxA 2 /PGH 2 receptor was excluded, as pD 2 (the negative logarithm of the molar concentration of agonist that elicits a half-maximal response) of U46619, an agonist for the TxA 2 /PGH 2 receptor, was identical before and after exposure to hypoxia-reoxygenation (7.7 Ϯ 0.5 vs. 7.8 Ϯ 0.5). A correspondent dose of PGE 2 (20 ng/ml) applied to the bath solution did not cause vasoconstriction (data not shown), indicating that the higher levels of PGE 2 after hypoxia-reoxygenation were not responsible for the second constriction phase.
According to our working hypothesis, hypoxia-reoxygenation could induce peroxynitrite formation, which inactivates PGI 2 synthase. To test whether peroxynitrite was indeed responsible for the hypoxia-reoxygenation-induced vasospasm, the NO synthase inhibitors, both L-NMMA (10 Ϫ4 M) and L-NAME (10 Ϫ4 M) were concurrently administered during hypoxia-reoxygenation. L-NMMA, which reduced the angiotensin II-induced relaxation phase by about 25% without affecting 6-keto-PGF 1␣ formation in normal vessels (data not shown), prevented hypoxia-reoxygenation-induced suppression of angiotensin II-induced vasorelaxation and 6-keto-PGF 1␣ release ( Fig. 1 A) ; L-NAME was as effective as L-NMMA (data not shown).
Alternatively, concurrent administration of PEG-SOD (500 U/ml) abolished hypoxia-reoxygenation-induced secondary vasoconstriction and restored angiotensin II-stimulated vasorelaxation by blunting the hypoxia-reoxygenationmediated inhibition on 6-keto-PGF 1␣ formation (Fig. 1 A) .
It was important to show that neither NO nor O 2
.Ϫ alone could cause vascular dysfunction and inhibition on PGI 2 release. Therefore, preincubation of BCA with an O 2 .Ϫ -generating system (10 mU/ml xanthine oxidase/100 M hypoxanthine) did not significantly affect either angiotensin II-triggered vasorelaxation or 6-keto-PGF 1␣ release (Fig. 1 B) . Alternatively, the incubation of BCA with DEA-NO (20 M) as an NO-releasing system also failed to affect angiotensin II-induced relaxation and 6-keto-PGF 1␣ release (Fig. 1 B) . However, concomitant administration to the organ baths of both O 2 .Ϫ -and NO-generating agents for 40 min caused a loss of PGI 2 -dependent vasorelaxation, an indomethacin-and SQ29548-sensitive vasospasm, and a nitration of PGH 2 synthase (Fig. 1 B) .
As previously described, the exposure of BCA to peroxynitrite produced a nitrated protein that colocalized with PGI 2 synthase (9). The same technique was applied to hypoxia-reoxygenation-exposed BCA segments after their mechanical responses had been established. Staining with antinitrotyrosine Ab was weakly visible in control tissue (Fig. 2 A) , but clearly enhanced stainings emerged in endothelium and smooth muscle after hypoxia-reoxygenation (Fig. 2 B) , where the stainings with Ab against PGI 2 synthase were intensively presented (Fig. 1 C) . A computergenerated overlay of the stainings with antinitrotyrosine (green) and anti-PGI 2 synthase (red) resulted in the yellow colocalizing patches in vessels after hypoxia-reoxygenation (Fig. 2 D) . The presence of L-NMMA or PEG-SOD abolished the increased stainings with antinitrotyrosine Ab (Fig. 2 , F and G) but not those with anti-PGI 2 synthase Ab (data not shown). The specificity of the staining with antinitrotyrosine Ab was deduced from its suppression by 10 mM 3-nitrotyrosine (Fig. 2 E) and the lack of staining when antinitrotyrosine Ab was omitted (Fig. 2 H) . 3-chloro-or 3-aminotyrosine or phosphotyrosine were ineffective in blocking the stainings with antinitrotyrosine Ab (data not shown).
Further evidence for hypoxia-reoxygenation-triggered tyrosine nitration of PGI 2 synthase came from the immunoprecipitation with both antibodies against 3-nitrotyrosine and PGI 2 synthase. Immunoprecipitation with anti-PGI 2 synthase Ab yielded similar amounts of protein in both hypoxiareoxygenation-treated arteries and control tissues (Fig. 3 A) . In Western blot analysis, a dense band was detected by antinitrotyrosine Ab in the immunoprecipitates with anti-PGI 2 synthase Ab from hypoxia-reoxygenation-treated vessel homogenates against a weakly visible signal in those from the control tissues (Fig. 3 A) . In the same homogenates, 3-nitrotyrosine-containing proteins were precipitated with antinitrotyrosine Ab in parallel. Higher amounts of these proteins were recovered in hypoxia-reoxygenation-treated arteries than in those without hypoxia-reoxygenation. Moreover, when these precipitates were blotted and probed with anti-PGI 2 synthase Ab, a dense staining appeared in arteries with hypoxia-reoxygenation (Fig. 3 B) . In agreement with the immunohistochemistry results, both PEG-SOD and L-NMMA effectively abolished the increased stainings with both antibodies in the immunoprecipitates with either antinitrotyrosine or anti-PGI 2 synthase (Fig. 3, A and B) .
In summary, our results indicate that hypoxia-reoxygenation elicits the formation of O 2 .Ϫ , which neutralize NO to form peroxynitrite. Subsequently, peroxynitrite nitrates and inactivates PGI 2 synthase, leaving PGH 2 unmetabolized, which then causes vasospasm and platelet aggregation via the TxA 2 /PGH 2 receptor. This finding might offer a new mechanism for coronary vasospasm during hypoxia-reoxygenation, especially in atherosclerotic arteries where PGI 2 synthase is partially nitrated (15) .
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